This was the stock's second consecutive day of gains.

Catalyst Pharmaceuticals Inc. closed 13.60% below its 52-week high of $26.16, which the company reached on March 24th.

BofA raised the firm’s price target on Catalyst Pharmaceuticals (CPRX) to $34 from $33 and keeps a Buy rating on the shares. The firm, in its ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Catalyst Pharma (CPRX – Research Report), ...